Global market

  • 11% of the world's population is affected by irritable bowel syndrome (IBS), a disease that is in the top 10 most difficult diseases to diagnose according to Fleming's list.
  • There is no positive diagnostic test for IBS, currently its diagnosis consists of performing a series of tests to rule out other diseases that may mimic IBS.
  • Inflammatory bowel disease (IBD), which affects 50 million people worldwide, is one of the diseases that can mimic IBS and its diagnosis calls for invasive testing.
  • It is estimated that up to 45% of patients wait more than 1 year for the diagnosis of these pathologies, while up to 17% wait more than 5 years.

Our proposal

IBS and IBD are chronic intestinal diseases that are characterized by intermittent periods of relapses of activity or remission, which complicates the initial diagnosis and follow-up of these diseases with invasive techniques and aggressive treatments.

Thanks to RAID-Dx, a non-invasive diagnosis of IBS can be performed in 7 days  by a stool test of high sensitivity and specificity that also distinguishes irritable bowel syndrome from inflammatory bowel disease without performing a colonoscopy.

RAID-Dx will significantly improve patients' quality of life.